Abiopharma

🔍 Evans Tyler Matthew (Director)

Company: Nakamoto Inc. (NAKA)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Sold 230 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: J | equity_swap_involved: 0 | shares_owned_after: 521,086.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 3 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: J | equity_swap_involved: 0 | shares_owned_after: 521,089.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 56,657 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: A | equity_swap_involved: 0 | shares_owned_after: 577,746.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 250,000 shares of Employee Stock Option (right to buy) at $7.06 per share (Derivative)
  Date: 2026-08-21 | Code: A | Expires: 2036-08-21 | equity_swap_involved: 0 | shares_owned_after: 885,544.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Reflects the forfeiture and cancellation of 230 shares of Common Stock, par value $0.001 per share ("Common Stock"), of Nakamoto Inc. (the "Issuer") for no consideration pursuant to that certain Agreement and Plan of Merger, dated as of February 16, 2026, by and among the Issuer, BTC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, BTC Inc., a Delaware corporation, and the stockholder representative party thereto.
• F2: Effective May 22, 2026, the Issuer effected a 1-for-40 reverse stock split of the Common Stock. The number of securities reported herein has been adjusted to reflect the reverse stock split.
• F3: Reflects the issuance of 3 shares of Common Stock received by the reporting person pursuant to that certain Agreement and Plan of Merger, dated as of February 16, 2026, by and among the Issuer, UTXO GP Merger Sub, LLC, a Tennessee limited liability company and a wholly-owned subsidiary of the Issuer, UTXO Management GP, LLC, a Tennessee limited liability company, David Bailey, in his individual capacity, the reporting person, in his individual capacity, and the equityholder representative party thereto.
• F4: Reflects restricted stock units ("RSUs") that shall time-vest over a 2-year period commencing on August 14, 2026, with no vesting during the first 12 months (the "RSU Cliff Period"), and thereafter, twenty-five percent (25%) of the RSUs shall vest upon completion of the RSU Cliff Period, with the remaining seventy-five percent (75%) vesting in equal quarterly installments over the following 12 months, subject to the RSU award agreement and the reporting person's continued employment or service to the Issuer through each applicable vesting date.
• F5: This option is designated an incentive stock option to the maximum extent permitted under Section 422 of the Internal Revenue Code of 1986, as amended, with the balance designated as a nonqualified stock option (the "Option").
• F6: The Option vests over a 4-year period commencing August 14, 2025, with no vesting during the first 12 months (the "Option Cliff Period"), and thereafter, twenty-five percent (25%) of the shares of Common Stock subject to the Option shall vest upon completion of the Option Cliff Period, with the remaining seventy-five percent (75%) of the shares of Common Stock subject to the Option vesting in equal quarterly installments over the following 36 months, subject to the Option award agreement and the reporting person's continued employment with the Issuer through each applicable vesting date. No portion of the Option was outstanding or exercisable prior to the date of grant, August 21, 2026; the portion vested as of that date by operation of the vesting schedule, representing 62,500 shares of Common Stock, became exercisable on the date of grant.